Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | NTRK2 positive |
Therapy | GNF-4256 + Irinotecan + Temozolomide |
Indication/Tumor Type | neuroblastoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NTRK2 positive | neuroblastoma | sensitive | GNF-4256 + Irinotecan + Temozolomide | Preclinical - Cell line xenograft | Actionable | In a preclinical study, GNF-4256 worked synergistically with Camptosar (irinotecan) and Temodar (temozolomide), resulting in growth inhibition and an increased event-free survival in cell line xenograft models of neuroblastoma expressing Ntrk2 (PMID: 25394774). | 25394774 |
PubMed Id | Reference Title | Details |
---|---|---|
(25394774) | TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts. | Full reference... |